171 related articles for article (PubMed ID: 29854236)
1. Causal Phenotyping for Susceptibility to Cardiotoxicity from Antineoplastic Breast Cancer Medications.
Sun D; Simon GJ; Skube S; Blaes AH; Melton GB; Zhang R
AMIA Annu Symp Proc; 2017; 2017():1655-1664. PubMed ID: 29854236
[TBL] [Abstract][Full Text] [Related]
2. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
4. CARDIOTOXICITY RISK PREDICTION IN BREAST CANCER PATIENTS.
Kozhukhov SM; Dovganych NV; Smolanka II; Lygyrda OF; Bazyka OY; Lyalkin SA; Ivankova OM; Yarinkina OA; Tkhor NV
Probl Radiac Med Radiobiol; 2021 Dec; 26():498-512. PubMed ID: 34965569
[TBL] [Abstract][Full Text] [Related]
5. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
6. Cancer drug related cardiotoxicity during breast cancer treatment.
Giordano G; Spagnuolo A; Olivieri N; Corbo C; Campagna A; Spagnoletti I; Pennacchio RM; Campidoglio S; Pancione M; Palladino L; Villari B; Febbraro A
Expert Opin Drug Saf; 2016 Aug; 15(8):1063-74. PubMed ID: 27120499
[TBL] [Abstract][Full Text] [Related]
7. [The role of biochemical markers with special regard to troponin, CK-MB, NT-proBNP as early biomarkers of cardiotoxicity among women after chemotherapy due to breast cancer].
Stachowiak P; Milchert-Leszczyńska M; Falco M; Polakowska M; Wojtarowicz A; Kaliszczak R; Safranow K; Kornacewicz-Jach Z
Przegl Lek; 2016; 73(6):359-63. PubMed ID: 29668198
[TBL] [Abstract][Full Text] [Related]
8. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
Guenancia C; Lefebvre A; Cardinale D; Yu AF; Ladoire S; Ghiringhelli F; Zeller M; Rochette L; Cottin Y; Vergely C
J Clin Oncol; 2016 Sep; 34(26):3157-65. PubMed ID: 27458291
[TBL] [Abstract][Full Text] [Related]
9. Phenotyping and Visualizing Infusion-Related Reactions for Breast Cancer Patients.
Sun D; Sarda G; Skube SJ; Blaes AH; Khairat S; Melton GB; Zhang R
Stud Health Technol Inform; 2017; 245():599-603. PubMed ID: 29295166
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
[TBL] [Abstract][Full Text] [Related]
11. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced cardiotoxicity in women.
Dempsey KS
Crit Care Nurs Clin North Am; 2008 Sep; 20(3):343-50. PubMed ID: 18644518
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
Wittayanukorn S; Qian J; Johnson BS; Hansen RA
J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
[TBL] [Abstract][Full Text] [Related]
15. [Cardiotoxicity as undesired side effect in the treatment of breast cancer].
Gramatyka M
Postepy Hig Med Dosw (Online); 2014 May; 68():483-97. PubMed ID: 24864100
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study.
Gunaldi M; Duman BB; Afsar CU; Paydas S; Erkisi M; Kara IO; Sahin B
J Oncol Pharm Pract; 2016 Apr; 22(2):242-7. PubMed ID: 25567518
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer.
Mihalcea DJ; Florescu M; Vinereanu D
Am J Ther; 2017; 24(1):e3-e11. PubMed ID: 27145188
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
19. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.
Pai VB; Nahata MC
Drug Saf; 2000 Apr; 22(4):263-302. PubMed ID: 10789823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
